Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559523 | HELSINN HLTHCARE | Compositions and methods for treating centrally mediated nausea and vomiting |
Nov, 2030
(7 years from now) |
Drugs and Companies using NETUPITANT; PALONOSETRON HYDROCHLORIDE ingredient
Market Authorisation Date: 10 October, 2014
Treatment: Method of treating emesis
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11357935
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Mar, 2039
(16 years from now) | |
US11464923
(Pediatric) | TEVA PHARM | Inhaler system |
Dec, 2040
(17 years from now) | |
US11439777
(Pediatric) | TEVA PHARM | Drug delivery device with electronics |
Nov, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jul 9, 2024 |
New Strength (NS) | Jul 9, 2024 |
Pediatric Exclusivity (PED) | Jan 9, 2025 |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 27 January, 2017
Treatment: NA
Dosage: POWDER;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11369567 | CMP DEV LLC | Aqueous suspension suitable for oral administration |
Jun, 2037
(14 years from now) |
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
Treatment: NA
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564917 | TEVA BRANDED PHARM | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Apr 3, 2024 |
M (M) | Jun 24, 2024 |
Pediatric Exclusivity (PED) | Oct 3, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 03 April, 2017
Treatment: Treatment of tardive dyskinesia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(18 years from now) | |
US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
48
United States
11
Japan
9
China
8
Australia
7
European Union
6
Hong Kong
6
Canada
5
Spain
3
Brazil
3
Korea, Republic of
3
South Africa
3
Israel
3
Denmark
2
Portugal
2
Singapore
2
Croatia
2
New Zealand
2
Argentina
2
Mexico
2
EA
2
Lithuania
2
Hungary
2
Poland
2
Chile
1
Colombia
1
Norway
1
Peru
1
Taiwan, Province of China
1
India
1
Cyprus
1
Slovenia
1
RS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8802637 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) | |
US7838499 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Jan, 2029
(5 years from now) | |
US8987323 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
May, 2032
(9 years from now) | |
US10981942 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jun, 2031
(8 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10533032 | THERACOSBIO | Crystalline form of benzylbenzene SGLT2 inhibitor |
Jul, 2031
(8 years from now) | |
US8106021 | THERACOSBIO | Benzylbenzene derivatives and methods of use |
Aug, 2028
(5 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 20, 2028 |
Drugs and Companies using BEXAGLIFLOZIN ingredient
NCE-1 date: 2027-01-20
Market Authorisation Date: 20 January, 2023
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11591340 | BEIGENE | NA |
Aug, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Nov 14, 2024 |
Orphan Drug Exclusivity (ODE) | Sep 14, 2028 |
New Indication (I) | Sep 14, 2024 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 2023-11-15
Market Authorisation Date: 14 November, 2019
Treatment: For the treatment of patients with waldenstrom's macroglobulinemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with chronic lymphocytic leukemia (cll) or small lymphocytic lymphoma (sll); Treatment of adult patients with chronic lymphocytic leukemia; Relapsed or refractory marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based regimen; Treatment of adult patients with small lymphocytic lymphoma
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11590228 | TRIS PHARMA INC | NA |
Sep, 2036
(13 years from now) |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 19 October, 2015
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: SUSPENSION, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11590081 | TRIS PHARMA INC | NA |
Sep, 2038
(15 years from now) |
Drugs and Companies using AMPHETAMINE; AMPHETAMINE ASPARTATE/DEXTROAMPHETAMINE SULFATE ingredient
Market Authorisation Date: 04 November, 2021
Treatment: Method of treating attention deficit hyperactivity disorder
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571398 | NEXUS PHARMS | NA |
May, 2040
(17 years from now) |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Market Authorisation Date: 17 April, 2020
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11534444 | GENENTECH INC | Treatment of SMA |
Oct, 2038
(15 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2029 |
New Chemical Entity Exclusivity (NCE) | Aug 7, 2025 |
New Patient Population (NPP) | May 27, 2025 |
Drugs and Companies using RISDIPLAM ingredient
NCE-1 date: 2024-08-07
Market Authorisation Date: 07 August, 2020
Treatment: Treatment of spinal muscular atrophy
Dosage: FOR SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 31 January, 2014
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11566011 | VANDA PHARMS INC | Highly purified pharmaceutical grade tasimelteon |
Feb, 2035
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Dec 1, 2023 |
Orphan Drug Exclusivity (ODE) | Dec 1, 2027 |
Drugs and Companies using TASIMELTEON ingredient
Market Authorisation Date: 01 December, 2020
Treatment: NA
Dosage: SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564933 | TOLMAR | Methods of treating testosterone deficiency |
Apr, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 27, 2022 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 27 March, 2019
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10695323 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
US10342780 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10918622 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) | |
US10464905 | LOXO ONCOL | Compounds useful as kinase inhibitors |
Dec, 2036
(13 years from now) |
Drugs and Companies using PIRTOBRUTINIB ingredient
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US11117871 | GLAXOSMITHKLINE | Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof |
Mar, 2038
(14 years from now) | |
US8324208 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Dec, 2028
(5 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815884 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) | |
US8557834 | GLAXOSMITHKLINE | Prolyl hydroxylase inhibitors |
Jun, 2027
(4 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Feb 1, 2028 |
Drugs and Companies using DAPRODUSTAT ingredient
NCE-1 date: 2027-02-01
Market Authorisation Date: 01 February, 2023
Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR ingredient
Market Authorisation Date: 17 March, 2015
Treatment: Treatment of cf in a patient age 4 months to <6 years who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916
Dosage: GRANULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564916 | VERTEX PHARMS | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using IVACAFTOR ingredient
Market Authorisation Date: 31 January, 2012
Treatment: Treatment of cf in a patient age 6 years and older who has one mutation in the cftr gene that is responsive to ivacaftor based on clinical and/or in vitro assay data using the composition recited in claim 1 of us 11564916
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11090386 | EISAI INC | Method for suppressing bitterness of quinoline derivative |
Feb, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Aug 15, 2025 |
M (M) | Dec 19, 2024 |
New Indication (I) | Aug 10, 2024 |
Drugs and Companies using LENVATINIB MESYLATE ingredient
Market Authorisation Date: 13 February, 2015
Treatment: Treatment with lenvima by administering lenvima as a suspension
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571328 | MEDICINES360 | NA |
Sep, 2040
(17 years from now) |
Drugs and Companies using LEVONORGESTREL ingredient
Market Authorisation Date: 26 February, 2015
Treatment: NA
Dosage: INTRAUTERINE DEVICE;INTRAUTERINE
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7378423
(Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Nov, 2027
(4 years from now) | |
US8835443
(Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
US8580304
(Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(9 years from now) | |
US9155706
(Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(9 years from now) | |
US8952018
(Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(8 years from now) | |
US9271941
(Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(9 years from now) | |
US8703781
(Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(8 years from now) | |
US10869869
(Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) | |
US9399021
(Pediatric) | NOVARTIS | Pharmaceutical composition |
Jul, 2032
(9 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
New Indication (I) | Jun 22, 2025 |
Pediatric Exclusivity (PED) | Oct 30, 2025 |
Drugs and Companies using TRAMETINIB DIMETHYL SULFOXIDE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571436 | BRISTOL | NA |
May, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 1, 2023 |
Orphan Drug Exclusivity (ODE) | Sep 1, 2027 |
Drugs and Companies using AZACITIDINE ingredient
Market Authorisation Date: 01 September, 2020
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571425 | INCYTE CORP | NA |
May, 2031
(8 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Sep 21, 2024 |
New Indication (I) | Jul 18, 2025 |
Pediatric Exclusivity (PED) | Mar 21, 2025 |
Drugs and Companies using RUXOLITINIB PHOSPHATE ingredient
Market Authorisation Date: 21 September, 2021
Treatment: NA
Dosage: CREAM;TOPICAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Strength (NS) | Sep 2, 2025 |
Orphan Drug Exclusivity (ODE) | Aug 7, 2025 |
New Patient Population (NPP) | Sep 2, 2025 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
Market Authorisation Date: 07 August, 2018
Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for the f508del mutation in the cftr gene using the composition recited in claim 1 of us 11564916
Dosage: GRANULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8399520 | STEMLINE THERAP | Selective estrogen receptor modulator |
Dec, 2023
(9 months from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10745343 | STEMLINE THERAP | Polymorphic forms of RAD1901-2HCl |
Jan, 2038
(14 years from now) | |
US10071066 | STEMLINE THERAP | Method of treating cancer using selective estrogen receptor modulators |
Oct, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jan 27, 2028 |
Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient
NCE-1 date: 2027-01-27
Market Authorisation Date: 27 January, 2023
Treatment: Treatment of an er-positive breast cancer; Treatment of an er-positive breast cancer following at least one line of endocrine therapy
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10456354 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(15 years from now) | |
US11110054 | SLAYBACK PHARMA LLC | Ready-to-use injectable pharmaceutical compositions comprising neostigmine and glycopyrrolate |
Oct, 2038
(15 years from now) |
Drugs and Companies using GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE ingredient
Market Authorisation Date: 23 February, 2023
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11576903 | DECIPHERA PHARMS | NA |
Dec, 2040
(17 years from now) | |
US11576904 | DECIPHERA PHARMS | NA |
Aug, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | May 15, 2025 |
Orphan Drug Exclusivity (ODE) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 2024-05-15
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumors in patients suffering from grade 2 or grade 3 arthralgia while being administered ripretinib daily
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559637 | NORTON WATERFORD | Inhalers and related methods |
Jul, 2039
(16 years from now) |
Drugs and Companies using BECLOMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 03 August, 2017
Treatment: NA
Dosage: AEROSOL, METERED;INHALATION
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11583542 | AMYLYX | NA |
Jul, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Sep 29, 2027 |
Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient
NCE-1 date: 2026-09-29
Market Authorisation Date: 29 September, 2022
Treatment: NA
Dosage: FOR SUSPENSION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11560354 | AXSOME MALTA | Compositions comprising (R)-2-amino-3-phenylpropyl carbamate and uses thereof |
Mar, 2039
(15 years from now) | |
US11160779 | AXSOME MALTA | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(17 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 17, 2024 |
Orphan Drug Exclusivity (ODE) | Jun 17, 2026 |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
NCE-1 date: 2023-06-18
Market Authorisation Date: 17 June, 2019
Treatment: Treatment of excessive daytime sleepiness by adminstering a composition comprising solriamfetol hydrochloride and 2-chloropropane, wherein the composition comprises less than about 5 ppm 2-chloropropane; Treatment of excessive daytime sleepiness by administering solriamfetol to a subject having mild, moderate, or severe renal impairment
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
New Chemical Entity Exclusivity (NCE) | Feb 12, 2023 |
Drugs and Companies using IVACAFTOR; IVACAFTOR, TEZACAFTOR ingredient
NCE-1 date: 2022-02-12
Market Authorisation Date: 12 February, 2018
Treatment: Treatment of cf in a patient age 6 years and older who is homozygous for f508del or has at least one cftr gene mutation responsive to tez/iva based on in vitro data and/or clinical evidence using the composition recited in us 11564916 claim 1
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(11 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 26 August, 2015
Treatment: Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of io mg or 25 mg of empagliflozin
Dosage: TABLET;ORAL
15
United States
4
Japan
3
China
3
Israel
2
Philippines
2
Korea, Republic of
2
Canada
2
Australia
2
European Union
1
Portugal
1
Spain
1
Croatia
1
New Zealand
1
Mexico
1
Hong Kong
1
EA
1
Lithuania
1
Poland
1
Chile
1
Finland
1
RS
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9949997 | BOEHRINGER INGELHEIM | Pharmaceutical composition, methods for treating and uses thereof |
May, 2034
(11 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 09 December, 2016
Treatment: Method for reducing the risk of cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes mellitus by once daily administration of empagliflozin; Method for reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin
Dosage: TABLET, EXTENDED RELEASE;ORAL
15
United States
4
Japan
3
China
3
Israel
2
Philippines
2
Korea, Republic of
2
Canada
2
Australia
2
European Union
1
Portugal
1
Spain
1
Croatia
1
New Zealand
1
Mexico
1
Hong Kong
1
EA
1
Lithuania
1
Poland
1
Chile
1
Finland
1
RS
1
Denmark
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7994185
(Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(7 years from now) | |
US8415345
(Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Jul, 2030
(7 years from now) | |
US9233956
(Pediatric) | NOVARTIS | Benzene sulfonamide thiazole and oxazole compounds |
Nov, 2029
(6 years from now) | |
US8952018
(Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-Raf inhibitors |
Apr, 2031
(8 years from now) | |
US8835443
(Pediatric) | NOVARTIS | Pyrimidine compound and medical use thereof |
Dec, 2025
(2 years from now) | |
US8703781
(Pediatric) | NOVARTIS | Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors |
Apr, 2031
(8 years from now) | |
US10869869
(Pediatric) | NOVARTIS | Method of adjuvant cancer treatment |
Mar, 2034
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 22, 2024 |
New Indication (I) | Jun 22, 2025 |
Pediatric Exclusivity (PED) | Oct 30, 2025 |
Drugs and Companies using DABRAFENIB MESYLATE ingredient
Market Authorisation Date: 29 May, 2013
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559530 | ANTARES PHARMA INC | Oral testosterone undecanoate therapy |
Nov, 2037
(14 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone; Primary hypogonadism (congenital or acquired); Hypogonadotropic hypogonadism (congenital or acquired).
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564886 | BOEHRINGER INGELHEIM | Pharmaceutical compositions |
Mar, 2032
(8 years from now) |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: Treatment of a type 2 diabetes patient with insufficient glycemic control despite metformin therapy using a composition comprising and extended release core comprising metformin and an outer coating comprising empagliflozin and linagliptin
Dosage: TABLET, EXTENDED RELEASE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564916 | VERTEX PHARMS INC | Pharmaceutical composition and administrations thereof |
Aug, 2029
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Jun 8, 2024 |
New Chemical Entity Exclusivity (NCE) | Oct 21, 2024 |
Orphan Drug Exclusivity (ODE) | Dec 21, 2027 |
Drugs and Companies using ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR ingredient
NCE-1 date: 2023-10-22
Market Authorisation Date: 21 October, 2019
Treatment: Treatment of cf in patients aged 6 years and older who have in the cftr gene at least one f508del mutation or a mutation that is responsive based on in vitro data by administering the composition recited in us 11564916 claim 1
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11559501 | NOVEN PHARMS INC | Transdermal amphetamine compositions with low levels of carbamate |
Jan, 2042
(18 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Product (NP) | Mar 22, 2025 |
Drugs and Companies using DEXTROAMPHETAMINE ingredient
Market Authorisation Date: 22 March, 2022
Treatment: NA
Dosage: SYSTEM;TRANSDERMAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11554229 | OPTINOSE US INC | Nasal administration |
Feb, 2036
(12 years from now) |
Drugs and Companies using FLUTICASONE PROPIONATE ingredient
Market Authorisation Date: 18 September, 2017
Treatment: Method of delivering fluticasone propionate to a nasal airway
Dosage: SPRAY, METERED;NASAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11571518 | ADAMIS PHARMS CORP | NA |
Jun, 2041
(18 years from now) |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a needle guard; A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syringe
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic